|The full article is available to subscribers||Subscriber Login|
Roflumilast (Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
STANDARD TREATMENT — The goals of drug therapy for COPD are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such as acute exacerbations. COPD exacerbations may hasten progression of the disease and lead to early mortality.
Patients with mild, intermittent COPD symptoms can be treated with an inhaled short-acting bronchodilator for symptom relief. When symptoms become more severe or persistent, an inhaled long-acting bronchodilator may be used. Combinations of a beta2-agonist with an anticholinergic can be used for patients inadequately... more
5. AWP listings according to Price Alert (July 15, 2011).